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ABSTRACT
Replication-competent adenoviruses may provide a highly efficient means of delivering therapeutic genes to
tumors. Previously, we evaluated in vitro a replication-competent adenovirus (Ad5-CD/TKrep) containing a
cytosine deaminase (CD)/herpes simplex type 1 thymidine kinase (HSV-1 TK) fusion gene that allows lytic vi-
ral therapy to be combined with double suicide gene therapy. Both the CD/5-FC and HSV-1 TK/GCV en-
zyme/prodrug systems enhanced the tumor cell-specific cytopathic effects of the Ad5-CD/TKrep virus in vitro
and sensitized cells to radiation. To extend these in vitro findings in vivo, we evaluated the antitumor activity
of the Ad5-CD/TKrep virus in combination with double prodrug therapy and radiation therapy. The Ad5-
CD/TKrep virus independently demonstrated significant antitumor activity against C33A cervical carcinoma
xenografts. Therapeutic outcome was dramatically improved with systemic administration of double, but not
single, prodrug (5-FC 1 GCV) therapy. When used in a neoadjuvant  setting, Ad5-CD/TKrep-mediated dou-
ble suicide gene therapy dramatically potentiated the effectiveness of radiation therapy. The trimodal ap-
proach of Ad5-CD/TKrep viral, double suicide gene, and radiotherapies produced significant tumor regres-
sion and ultimately 100% tumor cure. The results demonstrate the high therapeutic potential of the trimodal
approach and provide a solid foundation for future clinical trials.
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OVERVIEW
The ability of double suicide gene therapy to improve the
antitumor efficacy of a cytolytic adenovirus was examined
utilizing an E1B-attenuated, replication-com petent adeno-
virus (Ad5-CD/TKrep) encoding a CD/HSV-1 TK fusion
gene. Despite the inability of the individual CD/5-FC and
HSV-1 TK/GCV system s to enhance viral therapy, double
suicide gene therapy, employing both 5-FC and GCV pro-
drugs, markedly enhanced the therapeutic effectiveness of
the lytic Ad5-CD/TKrep virus. Consistent with the ability
of CD/5-FC and HSV-1 TK/GCV enzyme/prodrug system s
to function as effective neoadjuvants to radiotherapy, Ad5-
CD/TKrep-mediated double suicide gene therapy markedly
sensitized adenovirally infected tumors to c radiation. Con-
comitant adenoviral, double suicide gene, and radiothera-
pies resulted in significant tumor regression and tumor
cure, demonstrating the therapeutic potential of the tri-
modal anticancer approach.
INTRODUCTION
AV ARIETY OF cancer gene therapies have been developed andproven effective against experimental tumors in vivo . For
a given cancer gene therapy to be clinically successful, how-
ever, it must selectively destroy malignant cells while mini-
mizing damage to normal tissue. One approach that has proven
effective at increasing the differential response between tumor
and normal tissue is suicide gene therapy. Suicide gene therapy
involves the tumor-targeted delivery of genes encoding meta-
bolic enzymes that convert systemically delivered, innocuous
prodrugs into toxic metabolites. This results in a high concen-
tration of toxic product intratumorally, thereby avoiding the sys-
temic toxicity often associated with conventional chemother-
apy (e.g., 5-fluorouracil [5-FU]). Two suicide gene systems that
have been studied intensely are herpes simplex type 1 thymi-
dine kinase (HSV-1 TK)/ganciclovir (GCV) and Escherichia
coli cytosine deaminase (CD)/5-fluorocytosine (5-FC). HSV-1
TK phosphorylates GCV, converting it to a nucleotide analog
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that inhibits DNA synthesis (DeClercq, 1984), while CD con-
verts 5-FC to its highly toxic metabolite, 5-FU (Calabresi and
Chabner, 1990).
Effective cancer gene therapy also requires an efficient and
reproducible method of in vivo gene delivery. Currently, re-
combinant adenoviruses represent the most efficient means of
delivering genes to solid tumors. Preclinical studies have
demonstrated a high efficiency of gene transfer and effective
tumor control after regional delivery of replication-defect ive,
CD- or HSV-1 TK-containing adenoviruses, coupled with 5-FC
or GCV therapy (Chen et al., 1994; Hirschowitz et al., 1995;
Dong et al., 1996; Eastman et al., 1996; Ohwada et al., 1996;
Block et al., 1997; Evoy et al., 1997; Hall et al., 1997; Sutton
et al., 1997).
In an attempt to improve the efficacy of these monothera-
pies, we previously coupled the CD/5-FC and HSV-1 TK/GCV
enzyme/prodrug systems and pioneered the concept of using
them as a neoadjuvant to radiation therapy (Kim et al., 1994,
1995, 1997, 1998; Khil et al., 1996; Rogulski et al., 1997a,b;
Freytag et al., 1998; Gable et al., 1998). We used a CD/HSV-
1 TK fusion gene to demonstrate that double suicide gene ther-
apy is markedly more efficacious than either single gene ther-
apy (Rogulski et al., 1997a,b). Moreover, when used as a
neoadjuvant to radiation therapy, double suicide gene therapy
sensitized tumors to the toxic effects of radiation (i.e., ra-
diosensitization), resulting in markedly better tumor control and
cure. On the basis of these findings, we believe that double sui-
cide gene therapy, when used as a neoadjuvant to radiation ther-
apy, will demonstrate efficacy in the clinic provided that the
CD/HSV-1 TK fusion gene can be delivered efficiently and se-
lectively to the tumor site.
In an attempt to increase the efficiency of gene expression
and delivery, we developed a replication-com petent adenovirus
(Ad5-CD/TKrep) containing the CD/HSV-1 TK fusion gene
(previously called FGR; Freytag et al., 1998). The replicative
capacity of the Ad5-CD/TKrep virus results in much greater
(up to 2000-fold) transgene expression per cell relative to repli-
cation-defective adenoviruses (Freytag et al., 1998) and has the
potential to improve the gene transduction efficiency (percent-
age of tumor cells infected) via viral spread. Moreover, because
Ad5-CD/TKrep is cytolytic, the virus itself provides a power-
ful therapeutic modality that is not possible with replication-
defective adenoviruses. Ad5-CD/TKrep effectively destroyed
tumor cells in vitro while displaying minimal cytotoxicity to-
ward normal cells (Freytag et al., 1998). Moreover, both the
CD/5-FC and HSV-1 TK/GCV suicide gene systems augmented
the tumor cell-specific cytopathic effects of the Ad5-CD/TKrep
virus and sensitized tumor cells to radiation. We have now ex-
tended these in vitro findings in vivo by demonstrating that dou-
ble suicide gene therapy augments significantly the antitumor
activity of Ad5-CD/TKrep and that both modalities, when com-
bined, are an effective neoadjuvant to radiation therapy.
MATERIALS AND METHODS
Cell lines and recombinant adenoviral vectors
C33A cells, obtained from American Type Culture Collec-
tion (ATCC, Rockville, MD), were maintained in Dulbecco’s
modified Eagle’s medium (DMEM) supplemented with 10%
fetal bovine serum (FBS) and nonessential amino acids. The
construction and generation of the E1B-attenuated , replication-
competent Ad5-CD/TKrep adenovirus (previously called FGR)
and its replication-defecti ve counterpart, Ad5-FGNR (previ-
ously called Ad5-CDgly TK), have been described previously
(Freytag et al., 1998). The names of the viruses were changed
per the recommendation of the Food and Drug Administration
(FDA). Adenoviral titers were determined by plaque assay, us-
ing HEK293 cells (Graham and Prevec, 1991), and are ex-
pressed as plaque-forming units (PFU).
Prodrug sensitivity assays
Cells (5 3 105/60-mm dish) were either mock infected or in-
fected with Ad5-FGNR at a multiplicity of infection (MOI) of
100 in 1 ml of DMEM with 2% FBS. After 1 hr, cells were re-
plated (1.5 3 104 cells/well, 24-well plate) in DMEM contain-
ing 10% FBS (growth medium). Seventy-two hours postinfec-
tion, the medium was removed and replaced with fresh medium
without or with 5-FC (Sigma, St. Louis, MD) or GCV (Syntex,
Palo Alto, CA). Cells were cultured in the presence of prodrugs
for 96 hr. Cell viability was determined by the MTT [3-(4,5-di-
methylthiazol-2-yl)-2,5 -diphenyltetrazolium bromide; Sigma]
assay according to the manufacturer protocol.
Ad5-CD/TKrep viral replication in the presence 
of prodrugs
C33A cells (106/60-mm dish) were either mock infected or
infected with Ad5-CD/TKrep at an MOI of 10 in 0.2 ml of
DMEM with 2% FBS. After 1 hr, the medium was removed
and cells were immediately replated (2 3 104 cells/well, 24-
well plate) in varying concentrations of 5-FC or GCV. Low
molecular weight DNA was isolated 48 hr postinfection and an-
alyzed by Southern blotting as previously described (Freytag et
al., 1998).
In vivo adenovirus-mediated suidide gene therapy
Five- to 6-week-old female athymic mice (nu/nu [CD-1];
Charles River Laboratories, Wilmington, MA) were used in all
studies. C33A tumors were established by inoculating 2 3 106
cells prepared in 0.9% NaCl and 15% Matrigel (Collaborative
Biomedical Products, Bedford, MA), subcutaneously over the
abdomen or intram uscularly within the right gastrocnemius
muscle. On reaching 100 mm3 (subcutaneous) or 120 mm3 (in-
tramuscular), tumors were injected with 108 PFU of Ad5-
CD/TKrep or phosphate-buffere d saline (PBS, 50 m l) for five
consecutive days (days 0–4). Daily injections were distributed
evenly throughout the tumor. At the conclusion of the viral in-
oculations, mice in the prodrug treatment groups received in-
traperitoneal injections of 5-FC (500 mg/kg), GCV (60 mg/kg),
or 5-FC (500 mg/kg) 1 GCV (60 mg/kg). Prodrugs were ad-
ministered daily as indicated in Figs. 1 and 3. Tumors were
measured every 2–3 days. Tumor volume was determined by
three-dimension al caliper measurements .
Radiation therapy
As detailed above, C33A cells were implanted into the right
gastrocnemius muscle. Intramuscular, rather than subcutaneous,
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tumors are used to minimize stretching of the skin, which can
lead to unacceptable ulceration after irradiation. When tumors
reached 120 mm3, animals received five daily intratum oral in-
jections of Ad5-CD/TKrep or PBS (days 0–4). After the last
viral injection (day 4), Ad5-CD/TKrep-treated mice were di-
vided into two groups (Ad5-CD/TKrep, Ad5-CD/TKrep 1 5-
FC 1 GCV; 10 animals per group). Prodrug-treated  animals re-
ceived daily injections of 5-FC (500 mg/kg) and GCV (60
mg/kg) for either 4 or 7 days, as indicated in Figs. 1 and 3, be-
ginning on day 4. On the day of irradiation, the two treatment
groups were further subdivided into four groups (five animals
per group) based on comparable tumor volumes: Ad5-
CD/TKrep, Ad5-CD/TKrep 1 radiation treatm ent (RT), Ad5-
CD/TKrep 1 5-FC 1 GCV, and Ad5-CD/TKrep 1 5-FC 1
GCV 1 RT. Radiation was delivered to the tumored leg 2 hr
after prodrugs were given for that day. For radiation response
controls, five uninjected tumors with volumes comparable to
those within the Ad5-CD/TKrep 1 RT and Ad5-CD/TKrep 1
5-FC 1 GCV 1 RT groups were also irradiated. Animals in the
radiation treatment groups were anesthetized by intraperitoneal
injection of Nembutal (60 mg/kg) and a single dose of 60Co g -
radiation (8 or 10 Gy) was delivered to the tumor-bearing leg
as described previously (Rogulski et al., 1997b). Volumes of
intramuscular leg tumors were determ ined by the follow ing for-
mula (Alfieri and Hahn, 1978): d 9 3 2 (0.6)2d 9 5 volum e (cm3),
where d 9 is the average diameter of the tumored leg (cm) and
the product (0.6)2d 9 is the correction factor for nomal leg vol-
ume. For all tumor studies, animals were followed until death
(euthanasia) from tumor burden or for at least 90 days after ces-
sation of treatment. All animal experiments were approved by
the Care of Experimental Animal Committee of Henry Ford
Hospital (Detroit, MI). An extensive toxicology study has been
completed with the Ad5-CD/TKrep virus without and with dou-
ble prodrug therapy after intraprostatic administration in
C57BL/6 mice. The results of these studies will be made avail-
able to any investigator on request.
RESULTS
Double suicide gene therapy augments the antitumor
activity of the replication-competent 
Ad5-CD/TKrep adenovirus
The therapeutic efficacy of the CD/5-FC and HSV-1
TK/GCV suicide gene systems in the context of the replication-
competent Ad5-CD/TKrep adenovirus was evaluated using the
human C33A (cervical carcinom a) tumor xenograft. Subcuta-
neous abdominal tumors (100 mm3) were injected with either
PBS or Ad5-CD/TKrep (108 PFU) for five consecutive days.
As both suicide gene systems were previously demonstrated to
interfere with Ad5-CD/TKrep replication (Freytag et al., 1998),
prodrug therapy commenced shortly after completion of viral
inoculation to allow for viral replication and spread. In initial
studies, prodrug therapy was continued until tumors stopped re-
gressing ( , 3 weeks).
Intratumoral inoculation of Ad5-CD/TKrep itself resulted in
a significant tumor growth delay of 25 days (p 5 0.015;
ANOVA relative to PBS-injected controls (Fig. 1A). This was
not a nonspecific effect of adenoviral injection, as parallel tu-
mors injected with a replication-defective version of Ad5-
CD/TKrep, Ad5-FGNR (Freytag et al., 1998), resulted in a tu-
mor growth delay (7 days) that was not significantly different
from the control group (Fig. 1A). Thus, as expected, Ad5-
CD/TKrep itself, via its cytolytic activity, provides significant
tumor control. The efficacy of Ad5-CD/TKrep viral therapy was
markedly enhanced by double suicide gene therapy. On day 23,
when Ad5-CD/TKrep-treated tumors averaged , 125 mm3, those
treated with Ad5-CD/TKrep viral and double prodrug therapies
averaged only , 8 mm3, representing a 94% reduction in volume
relative to Ad5-CD/TKrep viral therapy alone. The combination
of Ad5-CD/TKrep viral and double prodrug therapies resulted in
a tumor growth delay of 66 days relative to PBS-injected con-
trols, which was significantly greater (p 5 0.011; ANOVA) than
Ad5-CD/TKrep therapy alone (Table 1). Importantly, no toxic-
ity (animal death or sustained weight loss) was observed after
Ad5-CD/TKrep viral and double prodrug therapies.
To determ ine whether the dramatic augmentation of Ad5-
CD/TKrep viral therapy by double prodrug therapy was attrib-
utable predominantly to one of the suicide gene systems, the
effects of combining Ad5-CD/TKrep viral therapy with 5-FC
or GCV prodrug therapy independently were also examined. As
pilot studies demonstrated that extending the prodrug therapy
regimen beyond 7 days did not result in significantly better tu-
mor control (our unpublished results, 1999), a 7-day prodrug
therapy regimen was adopted in subsequent experiments. As
was observed with the 21-day prodrug therapy regimen (Fig.
1A), 7 days of double prodrug therapy (Fig. 1B) resulted in
rapid tumor regression, ultimately yielding a tumor growth de-
lay of 67 days, which was more than three times that (20 days)
of Ad5-CD/TKrep viral therapy alone (Table 1). These results
demonstrate the reproducibility of the double prodrug therapy
effect, which was observed in eight independent experiments.
In marked contrast to double suicide gene therapy, neither the
CD/5-FC nor HSV-1 TK/GCV system significantly (p $ 0.2;
ANOVA) improved tumor control beyond that of Ad5-
CD/TKrep viral therapy alone. 5-FC therapy produced a mild,
transient enhancement of the Ad5-CD/TKrep viral effect,
which, in contrast with double prodrug therapy, was rapidly lost
on completion of the prodrug therapy course (Fig. 1B). GCV
therapy resulted in tumor growth kinetics that were essentially
identical to those of Ad5-CD/TKrep itself (Fig. 1B). These re-
sults demonstrate clearly that in the context of a replication-
competent adenovirus, double suicide gene therapy is thera-
peutically superior to single suicide gene therapy and
corroborate our previous findings with retrovirally transduced
tumor lines (Rogulski et al., 1997b).
The marked enhancement of Ad5-CD/TKrep viral therapy
by double prodrug therapy, despite the relative impotence of
the individual suicide gene system s, suggests synergistic inter-
actions between the CD/5-FC and HSV-1 TK/GCV systems,
which have been docum ented previously (Rogulski et al.,
1997a,b; Aghi et al., 1998; Uckert et al., 1998). The failure of
either suicide gene system to independently augment the anti-
tumor effects of the Ad5-CD/TKrep virus could derive from an
inherent insensitivity ot C33A tumor cells to the individual pro-
drugs, or a balance between suicide gene-mediated cytotoxic-
ity and inhibition of Ad5-CD/TKrep viral replication (Freytag
et al., 1998). To discern between these two possibilities, the
suicide gene-mediated effects were examined in vitro . For pro-
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drug sensitivity assays, C33A cells were infected with Ad5-
FGNR, a replication-defect ive version of Ad5-CD/TKrep
(Freytag et al., 1998), allowing suicide gene-mediated cyto-
toxicity to be analyzed independently from Ad5-CD/TKrep vi-
ral cytopathicity. Ad5-FGNR-infected C33A cells were sensi-
tive to both 5-FC and GCV in a concentration-depe ndent
manner, making it unlikely that the failure of these prodrugs to
enhance the Ad5-CD/TKrep viral effect in vivo was due to an
inherent insensitivity of C33A tumors to the prodrugs (Fig. 2A).
Analysis of Ad5-CD/TKrep replication in C33A cells revealed
that the HSV-1 TK/GCV system was effective at inhibiting vi-
ral replication (Fig. 2B). Indeed, the concentration of GCV re-
quired to completely inhibit Ad5-CD/TKrep viral replication in
vitro (0.2 m g/ml or 0.8 m M) is below that obtainable in humans
(2–30 m M) when using lower doses (15 mg/kg/day) of GCV.
The CD/5-FC system inhibited Ad5-CD/TKrep viral replica-
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TABLE 1. CO M PARISO N OF THER APEU TIC EFFEC TS OF Ad5-CD/TKrep VIR AL
TH ER APY W ITH O UT AN D W ITH SING LE AN D DOU BLE PRODRUG THER APIES
Average tumor growth delay (days) a
Treatmentb 21 days prodrug therapy 7 days prodrug therapy
Ad5-CD/TKrep 25 20
Ad5-CD/TKrep 1 5-FC ND 27
Ad5-CD/TKrep 1 GCV ND 20
Ad5-CD/TKrep 1 5-FC 1 GCV 66 67
aNumbers represent average tumor growth delay relative to PBS-injected controls. Each treatment
group contained five animals.
bAnimals were given daily intraperitoneal injections of 5-FC (500 mg/kg), GCV (60 mg/kg), or 
5-FC (500 mg/kg) 1 GCV (60 mg/kg) for either 21 or 7 days as indicated.
FIG. 1. Response of C33A tumors to Ad5-CD/TKrep virus and Ad5-CD/TKrep-mediated suicide gene therapies. (A) Subcu-
taneous abdominal C33A tumors (100 mm3) were injected with PBS or 108 PFU of Ad5-FGNR or Ad5-CD/TKrep virus for five
consecutive days (days 0–4, solid bar). Two days after the last virus injection (day 6), Ad5-CD/TKrep-injected animals were ei-
ther left untreated or administered 5-FC (500 mg/kg) and GCV (60 mg/kg) for 21 consecutive days (days 6–26, hatched bar).
The dotted line represents the predetermined end point of 400 mm3 . Each group contained five animals. (B) Subcutaneous ab-
dominal C33A tumors (100 mm3) were injected with either PBS or 108 PFU of Ad5-CD/TKrep virus for five consecutive days
(days 0–4, solid bar). Virus-injected animals were either left untreated or administered 5-FC (500 mg/kg), GCV (60 mg/kg), or
5-FC (500 mg/kg) and GCV (60 mg/kg) for seven consecutive days (days 6–12, hatched bar). Each group contained five ani-
mals. In this experiment only, the biological end point of 400 mm3 could not be used as one animal within the double prodrug
treatment group developed a large secondary tumor and had to be euthanized before the mean tumor volume of the group at-
tained 400 mm3. Thus, tumor growth delays were determined by using 200 mm4 as the end point. Note that this probably un-
derestimates the tumor growth delay of the double prodrug therapy group as the tumor growth rate of this group, after treatment,
was slower than that of the other groups.
A B
tion only at the highest concentration examined (100 m g/ml or
, 0.8 mM), which is well below the mean serum concentration
(3.8 mM) obtainable in mice with this dose (500 mg/kg/day) of
5-FC (Huber et al., 1993). Cumulatively , the in vitro analyses
suggest that the failure of either suicide gene system to inde-
pendently enhance the antitum or effects of the Ad5-CD/TKrep
virus likely results from a balance between suicide gene-medi-
ated cytotoxicity and inhibition of viral replication. Neverthe-
less, it is clear that despite the effects of these suicide gene 
systems on Ad5-CD/TKrep viral replication, when used con-
comitantly, they improve dramatically the efficacy of Ad5-
CD/TKrep viral therapy in vitro.
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FIG. 2. Effects of suicide gene systems on Ad5-CD/TKrep replication and cell survival. (A) In vitro sensitivity of C33A cells
to the CD/5-FC and HSV-1 TK/GCV enzyme/prodrug systems. Cells were infected with the replication-defecti ve Ad5-FGNR
virus at an MOI of 100. Seventy-two hours later, cells were treated with graded concentrations of 5-FC or GCV for 96 hr. Cell
viability was determined by the MTT assay. The results represent the mean of triplicate determinations. Error bars represent stan-
dard deviations. (B) Ad5-CD/TKrep viral replication in the presence of the 5-FC and GCV. C33A cells were either mock in-
fected (M) or infected with Ad5-CD/TKrep at an MOI of 10. Cells were detached and replated in varying concentrations of pro-
drugs. Cells were harvested 48 hr later for isolation of viral DNA. DNA was digested with HindIII and subjected to Southern
blot analysis. The 32P-labeled probe contains adenoviral type 5 sequences from base 1340 to the right end and detects all Ad5-
CD/TKrep viral HindIII fragments.
B
Potentiation of radiotherapy by Ad5-CD/TKrep-
mediated double suicide gene therapy
Using retrovirally transduced, radioresistant tumor lines sta-
bly expressing the CD/HSV-1 TK fusion gene, we demonstrated
previously that both the CD/5-FC and HSV-1 TK/GCV systems
can sensitize tumor cells to the toxic effects of radiation (Kim
et al., 1994, 1995, 1997, 1998; Khil et al., 1996; Rogulski et
al., 1997a; Freytag et al., 1998; Gable et al., 1998). Even greater
radiosensitization  is achieved when both enzym e/prodrug sys-
tems are used simultaneously (Rogulski et al., 1997a,b; Kim et
al., 1998). To assess the full potential of the trimodal (viral,
suicide gene, radiation) approach, Ad5-CD/TKrep-mediated
double suicide gene therapy was used as a neoadjuvant to ra-
diation therapy. Each single and dual modality was also eval-
uated to determ ine the contribution of each therapeutic arm. Be-
cause the radiation studies require that the body be shielded
during irradiation, C33A cells were inoculated intram uscularly
into the leg. After administration of the Ad5-CD/TKrep virus,
half of the animals received double prodrug therapy (days
4–10). Animals within the radiation treatment groups received
a single dose of g radiation to the tumored leg midway through
the prodrug course.
As observed in the subcutaneous model (Fig. 1A and B), Ad5-
CD/TKrep viral therapy alone resulted in a significant (p 5
0.0037; ANOVA) tumor growth delay of 29 days relative to PBS-
injected controls and 40% tumor cure (Fig. 3A, Table 2). No-
tably, with respect to tumor cure rate, Ad5-CD/TKrep viral ther-
apy was equivalent to 10 Gy of radiation, which demonstrates
clearly the benefit of using a cytolytic adenovirus as a gene ther-
apy vector (i.e., injection of the replication-defective Ad5-FGNR
virus yields no tumor cure; our unpublished results, 1999). As
expected, the addition of 7 days of double prodrug therapy
markedly enhanced both the tumor growth delay and cure rate
of Ad5-CD/TKrep viral therapy in the intramuscular model.
Whereas Ad5-CD/TKrep viral therapy itself resulted in an aver-
age tumor growth delay of 29 days and 40% cure, Ad5-
CD/TKrep viral and double prodrug therapies produced a tumor
growth delay of at least 100 days and 80% cure (Fig. 3A, Table
2). The basis for the greater efficacy observed in the intramus-
cular model (tumor growth delay . 100 days) relative to that
achieved in the subcutaneous model (tumor growth delay . 67
days) is unclear, but may be due to better tumor vascularization
resulting in more efficient prodrug delivery.
The trimodal Ad5-CD/TKrep viral, double suicide gene, and
radiotherapy approach resulted in significant tumor regression,
but ultimately produced the same tumor growth delay ( . . 100
days) and high cure rate (80%) as the combination of Ad5-
CD/TKrep viral and double prodrug therapies (Fig. 3A, Table
2). Because the combination of Ad5-CD/TKrep viral and dou-
ble suicide gene therapies was so effective in this regimen,
likely masking any radiosensitization effect, these studies were
repeated with an abbreviated prodrug therapy course (4 versus
7 days) and a lower dose of radiation (8 versus 10 Gy).
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FIG. 3. Effects of Ad5-CD/TKrep-mediated double suicide gene therapy on the radiation response of C33A leg tumors. (A)
Intramuscular C33A tumors (120 mm3) were injected with either PBS or 108 PFU of Ad5-CD/TKrep for five consecutive days
(days 0–4, solid bar). Animals receiving double prodrug therapy were administered 5-FC (500 mg/kg) and GCV (60 mg/kg) for
7 days beginning on day 4 (hatched bar). Animals within the radiation treatment groups received a single dose of 10 Gy to their
tumored limb on day 7. The dotted line represents the predetermined end point of 400 mm3. (B) Intramuscular C33A tumors
(120 mm3) were injected with either PBS or 108 PFU of Ad5-CD/TKrep for five consecutive days (days 0–4, solid bar). Ani-
mals receiving double prodrug therapy were administered 5-FC (500 mg/kg) and GCV (60 mg/kg) for 4 days beginning on day
4 (hatched bar). Animals within the radiation treatment groups received a single dose of 8 Gy to their tumored limb on day 6.
The dotted line represents the predeterm ined endpoint of 400 mm3.
A B
Independently, Ad5-CD/TKrep viral and radiation therapy
(8 Gy) each resulted in an average tumor growth delay of 42–45
days and 40 and 20% tumor cure, respectively (Fig. 3B, Table
3). In contrast to the 7-day prodrug therapy regimen (Fig. 3A),
the abbreviated 4-day regimen produced only a transient en-
hancem ent of the Ad5-CD/TKrep viral effect without improv-
ing therapeutic outcom e, yielding an average tumor growth de-
lay and cure rate (40%) identical to that of Ad5-CD/TKrep viral
therapy alone (Fig. 3B, Table 3). These results demonstrate the
critical importance of the length of the prodrug therapy regi-
men (4 days— same outcom e as Ad5-CD/TKrep viral therapy;
7 days— markedly better outcom e than Ad5-CD/TKrep viral
therapy). A profound antitumor effect resulted when combin-
ing Ad5-CD/TKrep viral, double suicide gene, and radiation
therapies (trimodal therapy). Rapid tumor regression occurred
shortly after radiation therapy (Fig. 3B). On day 18, when tu-
mors within all other treatment groups averaged between 40 to
180% of their pretreatment volumes, those within the trimodal
therapy group were apparently eradicated. Trimodal therapy re-
sulted in a tumor growth delay of at least 100 days a high cure
rate (80%), which was much greater than that achieved with
any other monotherapy or dual therapy. Such results were ob-
tained in two independent experiments. The one animal in the
trimodal therapy group that was not cured 90 days posttreat-
ment (60-mm3 tumor) became tumor free at 6 months, ulti-
mately yielding a cure rate of 100% . Thus, whereby shortening
the prodrug therapy course to 4 days essentially eliminated the
chemotherapeuti c effect of double prodrug therapy, the suicide
gene-mediated radiosensitization effect remained. The results
demonstrate that double suicide gene therapy, in the context of
the replication-comp etent Ad5-CD/TKrep adenovirus, is an ef-
fective neoadjuvant to radiation therapy.
DISCUSSION
We demonstrated previously in vitro the potential of the tri-
modal approach of Ad5-CD/TKrep viral, double suicide gene,
and radiation therapies. We now demonstrate in vivo that dou-
ble suicide gene therapy significantly enhances the antitumor
activity of the replication-com petent Ad5-CD/TKrep adeno-
virus and that these modalities, when combined, are an effec-
tive neoadjuvant to radiation therapy. Given that 50% of all hu-
man cancer patients are treated with radiation, it is possible that
Ad5-CD/TKrep viral and double suicide gene therapies will
demonstrate value in the clinic.
As demonstrated originally by us (Rogulski et al., 1997a,b;
Kim et al., 1998) and confirm ed subsequently by others (Aghi
et al., 1998; Uckert et al., 1998), double suicide gene therapy
is therapeutically superior to single suicide gene therapy. The
mechanism underlying the synergistic cytotoxicity of con-
comitant CD/5-FC and HSV-1 TK/GCV therapies is unclear,
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TABLE 3. COM PARISON O F THER APEU T IC EFFEC TS OF Ad5-CD/TKrep VIR A L, 
DOUBLE SUICIDE GEN E (4 DA Y), AND RA DIA TIO N TH ER APIES (8 Gy)
Average tumor Percentage tumor free at
Treatment growth delay (days) 90 days posttreatment
PBS NA 0 (0/5)
Ad5-CD/TKrep 45 40 (2/5)
8 Gy 42 20 (1/5)
Ad5-CD/TKrep 1 5-FC 1 GCV 45 40 (2/5)
Ad5-CD/TKrep 1 8 Gy 58 20 (1/5)
Ad5-CD/TKrep 1 5-FC 1 GCV 1 8 Gy @ 100a 80 (4/5)b
aNote that the mean tumor volume of the trimodal therapy group never reached the predetermined end point of 400 mm3 (even
after 6 months). Thus, a statistical analysis of the average tumor growth delays comparing the trimodal therapy group with the
other treatm ent groups could not be performed.
bThe one animal in this group that was not tumor free 90 days posttreatment had a 60-mm3 tumor and became tumor free at
6 months.
TA BL E 2. CO M PA RISO N OF TH ER APE UTIC EFFEC TS OF Ad5-CD/TKrep VIR AL, 
DOUBLE SUICIDE GEN E (7 DAY), AND RA DIA TIO N TH ER APIES (10 Gy)
Average tumor Percentage tumor free at
Treatment growth delay (days) 90 days posttreatment
PBS NA 0 (0/5)
Ad5-CD/TKrep 29 40 (2/5)
10 Gy 53 40 (2/5)
Ad5-CD/TKrep 1 5-FC 1 GCV @ 100a 80 (4/5)
Ad5-CD/TKrep 1 10 Gy 68 40 (2/5)
Ad5-CD/TKrep 1 5-FC 1 GCV 1 10 Gy @ 100a 80 (4/5)
aNote that the mean tumor volume of the Ad5-CD/TKrep 1 5-FC 1 GCV and trimodal therapy groups never reached the 
predeterm ined end point of 400 mm3 (even after 6 months). Thus, a statistical analysis of the average tumor growth delays of
these groups versus the other treatm ent groups could not be performed.
but may stem from the fact that the two suicide gene systems
target distinct, yet merging, biochemical pathw ays (Rogulski et
al., 1997a). As was shown here, double, but not single, suicide
gene therapy can enhance significantly the antitumor effects of
Ad5-CD/TKrep viral therapy. Independently, both the CD/5-
FC and HSV-1 TK/GCV systems failed to improve the antitu-
mor effects of the Ad5-CD/TKrep virus, despite their in vitro
cytotoxicity. Low efficacy of the CD/5-FC system in vivo, de-
spite in vitro potency, has been observed previously (Huber et
al., 1993; Trinh et al., 1995; Kievit et al., 1999) and may be
due to either inefficient conversion of the 5-FC substrate (Kievit
et al., 1999) or a requirement for an intact host immune sys-
tem (Consalvo et al., 1995). The failure of the HSV-1 TK/GCV
system to enhance the antitumor effects of the Ad5-CD/TKrep
virus in the C33A model appears to stem from a balance be-
tween suicide gene-mediated cytotoxicity and suppression of
viral replication. This antagonism may be tumor specific, as the
HSV-1 TK/GCV system has been demonstrated to enhance the
antitum or activity of a cytolytic virus in a colon xenograft
(Wildner et al., 1999). It should be noted, however, that a much
higher dose (200 mg/kg/day) of GCV was used in that study,
which is more than 3 times the dose used here and 10 times the
dose that can be safely used in humans (15–20 mg/kg/day).
In both the subcutaneous and intramuscular tumor models,
CD/5-FC and HSV-1 TK/GCV cotherapy achieved a potent an-
titumor effect in the context of the replication-com petent Ad5-
CD/TKrep adenovirus, suggesting that the combined cytotoxic
effects outweigh the suicide gene-mediated antiviral effects
(i.e., inhibition of viral replication and its accompanying cy-
tolysis). Hence, despite the apparent ability of the suicide gene
systems to interfere with Ad5-CD/TKrep viral replication, the
therapeutic benefits of combining double suicide gene therapy
with Ad5-CD/TKrep viral therapy are substantial. Because sui-
cide gene therapy requires prodrug administration, maximal vi-
ral spread and tumor destruction can be allowed to occur prior
to engaging the enzyme/prodrug systems (and radiation),
thereby minimizing the deleterious effects of inhibiting viral
replication.
Although the therapeutic benefits of coupling the CD/5-FC
and HSV-1 TK/GCV enzyme/prodrug system s and their use as
a neoadjuvant to radiation therapy are well documented (Rogul-
ski et al., 1997a,b; Aghi et al., 1998; Kim et al., 1998; Uckert
et al., 1998; and this report), an important issue not addressed
here is the yet unproven benefit of using a replication-comp e-
tent versus replication-defecti ve adenovirus to deliver the
CD/HSV-1 TK fusion gene. Replication-com petent adeno-
viruses have several theoretical advantages over replication-de-
fective viruses, some of which have been demonstrated. As
demonstrated here, Ad5-CD/TKrep itself, via its cytolytic ac-
tivity, results in a profound (20–45 days) tumor growth delay
and 40% tumor cure. Similar tumor growth delays have been
obtained in several other tumor models (subcutaneous DU145,
45 days; orthotopic LNCaP C4-2, 25 days). In contrast, the
replication-defecti ve counterpart of Ad5-CD/TKrep, Ad5-
FGNR, has demonstrated either little (C33A, 7 days) or no
(Hep3B, SK-OV-3; Xie et al., 1999) tumor growth delay and
no tumor cure in three tumor models. Second, as demonstrated
previously in vitro , replication-comp etent adenoviruses can re-
sult in markedly higher (up to 2000-fold) transgene expression
per cell via their ability to achieve a high copy number (Frey-
tag et al., 1998), which, in turn, should result in greater con-
version of prodrugs into their toxic metabolites. Third, replica-
tion-competent adenoviruses, via viral spread, have the poten-
tial to increase the in vivo gene transduction efficiency (per-
centage of tumor cells infected) relative to replication-defecti ve
viruses. Whether the latter possibility holds true in vivo is
presently unknown. Using the DU145 prostate adenocarcinoma
model, we have found that Ad5-CD/TKrep viral therapy alone
(108 PFU 3 5) results in a tumor growth delay (45 days) that
is essentially equivalent to that (42 days) of the replication-de-
fective Ad5-FGNR virus (108 PFU 3 5) and 14 days of dou-
ble prodrug therapy (our unpublished results, 1999). Consistent
with our observations, Wildner and co-workers demonstrated
that a cytolytic HSV-1 TK-expressing  adenovirus was as ef-
fective as a replication-defecti ve Ad.Tk vector and GCV pro-
drug therapy (Wildner et al., 1999). The therapeutic efficacy of
the cytolytic HSV-1 TK virus could be improved further with
high doses of GCV. Cumulatively,  these observations indicate
that the potency of suicide gene therapy will be greater in the
context of a replication-comp etent adenovirus than in a non-
replicating viral background.
Ad5-CD/TKrep is E1B attenuated and was modeled after
ONYX-015 (Bischoff et al., 1996), a virus originally hypoth-
esized to target only tumors of mutant p53 status by virtue of
its inability to express the p53-inactivati ng 55-kD a E1B pro-
tein (Yew and Berk, 1992). Much controversy has arisen re-
garding the selectivity of the E1B-attenuated adenoviruses
(Goodrum  and Ornelles, 1997, 1998; Hall et al., 1998; Roth-
mann et al., 1998; Harada and Berk, 1999; Turnell et al., 1999).
Hall and colleagues demonstrated that such viruses require
wild-type p53 function for effective replication and cytolysis
(Hall et al., 1998). Our results, and those of others (Harada
and Berk, 1999), conflict dramatically  with this tenet, as we
have found that Ad5-CD/TKrep lyses efficiently tumor cells
of both mutant (C33A, DU145, U251, HT-29) and wild-type
(LNCaP, RKO, A549, U343) p53 status in vitro (Freytag et
al., 1998; and our unpublished results, 1999), and results in
significant tumor growth delays with p53 wild-type (orthotopic
LNCaP C4-2, 25 days) and mutant (C33A, 20–45 days;
DU145, 45 days) tumors. Nonetheless, our in vitro observa-
tions regarding the host range specificity of the E1B-attenu-
ated adenoviruses do not agree well with the tenet originally
put forth by ONYX (Bischoff et al., 1996). Using isogenic tu-
mor cell lines that express either wild-type (RKO, U343) or a
dominant negative mutant (Arg-273 R His) of p53, we have
observed reproducibly that the Ad5-CD/TKrep and ONYX-
015 viruses replicate about three times faster in mutant p53
cells and that this can lead to slightly (two- to threefold) faster
cytolysis in vitro (Rogulski et al., 1999). Our observations
agree well with the results of Berk and colleagues, who found,
using a cell line expressing a temperature -sensitive mutant of
p53, that the dl1520 (ONYX-015) virus replicates slower ( , 3-
fold) and yields a markedly lower viral burst when p53 is ac-
tive (Harada and Berk, 1999). Along these same lines, using
the isogenic RKO/ RKOp53.13 tumor model (Slichenmyer et
al., 1993), we have found that ONYX-015 demonstrates greater
antitumor activity against mutant p53 tumors. Specifically,  in-
tratumoral injection of ONYX-015 (108 PFU 3 5) resulted in
a tumor growth delay with mutant p53 tumors (19 days) that
was significantly better (p , 0.001) than with wild-type tu-
mors (1 day) (Rogulski et al., 1999). It is possible that the dif-
ferential effect observed in vivo is related to the ability of the
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virus to replicate and, perhaps, spread faster in mutant p53 tu-
mors. Whether this is universally true will require confirm a-
tion in other isogenic tumor models.
Although conventional cancer therapies (surgery, chemo-
therapy, radiation therapy) are effective at curing early-stage
disease, few human cancers are curable with a single modality.
Without significant improvements in in vivo gene delivery, sui-
cide gene therapy, as a monotherapy, will have limited value
in the clinic. It has been our tenet that adenovirus-m ediated sui-
cide gene therapy will show the most promise when used as a
neoadjuvant to radiation therapy. Previously, we demonstrated
that both the CD/5-FC and HSV-1 TK/GCV systems could, in-
dependently, potentiate radiotherapy (Kim et al., 1994, 1995,
1997; Khil et al., 1996; Gable et al., 1998). Even greater ra-
diosensitization is achieved when both suicide gene systems are
combined (Rogulski et al., 1997a,b; Kim et al., 1998). We have
now extended these observations by demonstrating that double
suicide gene therapy, in the context of a replication-comp etent
adenovirus, can potentiate the therapeutic effects of radiation.
Combining Ad5-CD/TKrep viral and radiotherapies, in the ab-
sence of double prodrug therapy, does not significantly improve
tumor control beyond that of either monotherapy. In dramatic
contrast, therapeutic outcom e is markedly improved when the
suicide gene systems are engaged (trimodal therapy), even un-
der conditions in which the suicide gene systems themselves
produce no apparent chemotherapeuti c effect (i.e., 4 days of
prodrug therapy). These results demonstrate clearly that the
CD/5-FC and HSV-1 TK/GCV enzyme/prodrug systems can
function as true radiosensitizers in vivo, improving therapeutic
efficacy only through their synergistic interactions with radia-
tion.
Because human adenoviruses do not replicate efficiently in
mouse cells, human tumor xenografts in immunodeficie nt mice
had to be used in these studies. It remains to be determined
whether the dramatic results observed here can be achieved in
an immunocom petent host (i.e., patients). It is presently unclear
whether the host immune system  will prove to be a “friend”
(by generating an effective immune response to virally infected
tumor cells) or “foe” (by preventing viral spread) of cancer ther-
apies that utilize replication-com petent adenoviruses. The fact
that the ONYX-015 virus has demonstrated antitumor activity
in the clinic (Kirn et al., 1997) indicates that the immune sys-
tem does not block the cytolytic action of replication-comp e-
tent adenoviruses, at least with the initial dose. However, re-
peated doses appear to be less efficacious. Although the immune
system may preclude extensive viral spread, it may not neces-
sarily impede viral replication in infected cells. As described
above, an advantage of using replication-comp etent adeno-
viruses as gene therapy vectors is their ability to achieve a high
copy number resulting in significantly greater (up to 2000-fold;
Freytag et al., 1998) therapeutic transgene expression per cell.
Thus, even if the immune system  precludes viral spread, repli-
cation-competen t vectors should still result in greater thera-
peutic gene expression per viral dose relative to replication-de-
fective vectors. Moreover, although the immune system  may
attenuate the Ad5-CD/TKrep viral cytolytic effect, there is rea-
son to believe that it will augment the efficacy of CD/5-FC and
HSV-1 TK/GCV suicide gene therapies (Vile et al., 1994; Con-
salvo et al., 1995). Thus, the efficacy of the combined therapy
described here may depend on whether the antitumor effects of
host immune system (immune response to virally infected cells
and augmentation of suicide gene therapies) outweigh its neg-
ative effects on viral spread. The merit of this combined ap-
proach is best evaluated in the clinic, which will commence in
1999.
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